Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

被引：0

作者：

Jain, Nitin ^{[1
]}

Coombs, Catherine C. ^{[2
]}

D'Olimpio, James ^{[3
]}

Shah, Nirav N. ^{[4
]}

Barrientos, Jacqueline C. ^{[5
]}

Lee, Seung Tae ^{[6
]}

Gillis-Smith, Andrew ^{[7
]}

Ma, Shuo ^{[8
]}

Kirita, Shirou ^{[9
]}

Sawa, Masaaki ^{[9
]}

Miyamoto, Kyoko ^{[10
]}

Arimura, Akinori ^{[10
]}

Wierda, William G.

Gandhi, Varsha ^{[11
]}

Pinilla-Ibarz, Javier ^{[12
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Calif Irvine, Irvine, CA USA

[3] Clin Res Alliance, Westbury, NY USA

[4] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA

[5] Mt Sinai Med Ctr, Miami Beach, FL USA

[6] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA

[7] Univ Massachusetts, Mem Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA

[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA

[9] Carna Biosci Inc, Kobe, Japan

[10] CarnaBio USA Inc, South San Francisco, CA USA

[11] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX USA

[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

来源：

关键词：

D O I：

10.1182/blood-2024-208549

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1866 / 1867

页数：2